Advicenne

Company snapshot

Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. Advicenne have spent more than 10 years developing products for the treatment of rare renal diseases. At Advicenne, we are committed to developing and commercializing medicines that are suitable for both children and adults – groundbreaking treatments for rare diseases

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Advicenne. Not investment advice.

• What is Advicenne?

  Advicenne is a pharma organization headquartered in EU. Primary therapeutic focus areas include distal renal tubular acidosis (dRTA). NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and

• Is Advicenne publicly traded?

  Advicenne appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Advicenne develop or market?

  We link 2 drug profile(s) where Advicenne is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/advicenne-s-a#company-drugs.

• What are the latest developments for Advicenne?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Advicenne focus on?

  Advicenne focuses on distal renal tubular acidosis (dRTA) based on our analysis of their pipeline programs and drug development activities.